PT  - JOURNAL ARTICLE
ED  - , 
TI  - Alectinib Approved for ALK+ Lung Cancer
AID  - 10.1158/2159-8290.CD-NB2016-001
DP  - 2016 Feb 01
TA  - Cancer Discovery
PG  - 115--115
VI  - 6
IP  - 2
4099  - http://cancerdiscovery.aacrjournals.org/content/6/2/115.1.short
4100  - http://cancerdiscovery.aacrjournals.org/content/6/2/115.1.full
SO  - Cancer Discov2016 Feb 01; 6
AB  - The FDA has approved a third ALK inhibitor, alectinib, for advanced ALK-positive non–small cell lung cancer. Two phase II studies show that patients who have become resistant to crizotinib respond well to alectinib; the drug is also effective against brain metastases, which are common in this disease subtype.